| Title: |
Effectiveness of Dual Versus Triple Inhaled Therapy in Chronic Obstructive Pulmonary Disease Patients: Results from a Quasi-Experimental Study, Multan |
| Authors: |
Sidra Batool; Javed Ahmed Khan; Faryal Asmat; Hamna Wajid; Zoha Hashmi |
| Source: |
Life and Science, Vol 6, Iss 4, Pp 07-07 (2025) |
| Publisher Information: |
National University of Medical Sciences, 2025. |
| Publication Year: |
2025 |
| Collection: |
LCC:Science |
| Subject Terms: |
beta-2 agonists, chronic obstructive pulmonary disease, corticosteroid, muscarinic antagonist; Science |
| Description: |
Objective: To compare the efficacy of dual inhaled therapy and triple inhaled therapy in chronic obstructive pulmonary disease patients. Study Design: Quasi-experimental study. Place and Duration of Study: This study was conducted at the Department of Medicine, Combined Military Hospital (CMH), Multan, Pakistan from 1st January 2023 to 31st December 2023. Methods: A total of 60 patients with chronic obstructive pulmonary disease were included in this study and allocated to 2 equal groups based on clinical criteria. In Group-D, patients were given dual inhaled inhaler therapy (Corticosteroid+ Long acting β-2 agonists) while patients in Group-T were given triple inhaled inhaler therapy (Corticosteroid+ Long acting β-2 agonists+ long-acting muscarinic antagonist) twice daily. The primary outcome was set as the percentage of patients achieving a reduced number of moderate-severe exacerbations, while the secondary outcomes included improved post-dose forced expiratory volume, number of patients achieving improved chronic obstructive pulmonary disease assessment test score, and baseline dyspnea index focal score after 6 months of treatment. Results: The results of primary outcomes showed significantly better efficacy in Group-T compared to Group-D, as a considerably higher number of patients had reduced frequency of moderate-severe chronic obstructive pulmonary disease exacerbations after 6 months (86.66% vs 53.33%, P=0.035). There was also significant improvement in secondary outcomes, including post-dose forced expiratory volume in 1 second, patients who had improved assessment test scores, as well as baseline dyspnea index focal score in Group-T compared to Group-D. Conclusion: Triple inhaled therapy is more effective than dual inhaled therapy for reducing moderate-to-severe chronic obstructive pulmonary disease exacerbations. How to cite this: Batool S, Khan JA, Asmat F, Wajid H, Hashmi Z. Effectiveness of Dual Versus Triple Inhaled Therapy in Chronic Obstructive Pulmonary Disease Patients: Results from a Quasi-Experimental Study, Multan. Life and Science. 2025; 6(4): 430-436. doi: http://doi.org/10.37185/LnS.1.1.763 |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2521-0475; 2708-2970 |
| Relation: |
https://lifenscience.org/index.php/life-and-science/article/view/763; https://doaj.org/toc/2521-0475; https://doaj.org/toc/2708-2970 |
| DOI: |
10.37185/LnS.1.1.763 |
| Access URL: |
https://doaj.org/article/d7e4eec5e0fd462e9c03377cf6ddffe3 |
| Accession Number: |
edsdoj.7e4eec5e0fd462e9c03377cf6ddffe3 |
| Database: |
Directory of Open Access Journals |